Myelofibrosis Market

DelveInsight’s Myelofibrosis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, March 29, 2024 /EINPresswire.com/ -- DelveInsight’s “Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myelofibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myelofibrosis Market Forecast

Some of the key facts of the Myelofibrosis Market Report:
The Myelofibrosis market size is anticipated to grow with a significant CAGR of 7.3 % during the study period (2019-2032
In November 2023, MorphoSys disclosed favorable initial findings from the Phase III MANIFEST-2 trial, which investigated the BET inhibitor pelabresib combined with the JAK inhibitor ruxolitinib, in comparison to placebo plus ruxolitinib, among myelofibrosis patients who had not previously received JAK inhibitors.
In September 2023, OJJAARA (momelotinib) received approval from the US FDA as the initial and sole therapy specifically for myelofibrosis patients with anemia.
Across various studies conducted in European nations, the annual prevalence of myelofibrosis varied between 0.5 to 9 cases per 100,000 individuals.
In diverse investigations conducted in European countries, the yearly occurrence rate of myelofibrosis fluctuated from 0.5 to 9 instances per 100,000 people.
In 2023, the overall prevalent population of myelofibrosis in the 7MM was approximately 40,000 cases and is expected to rise over the study duration from 2019 to 2032.
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others
The Myelofibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myelofibrosis pipeline products will significantly revolutionize the Myelofibrosis market dynamics.

Myelofibrosis Overview
Myelofibrosis is a rare type of bone marrow disorder characterized by the abnormal production of blood cells, leading to scarring (fibrosis) in the bone marrow. In this condition, the bone marrow becomes increasingly fibrous, impairing its ability to produce normal blood cells. This can result in a decrease in the production of red blood cells, white blood cells, and platelets.

Get a Free sample for the Myelofibrosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Myelofibrosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myelofibrosis Epidemiology Segmentation:
The Myelofibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Myelofibrosis
Prevalent Cases of Myelofibrosis by severity
Gender-specific Prevalence of Myelofibrosis
Diagnosed Cases of Episodic and Chronic Myelofibrosis

Download the report to understand which factors are driving Myelofibrosis epidemiology trends @ Myelofibrosis Epidemiology Forecast

Myelofibrosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelofibrosis market or expected to get launched during the study period. The analysis covers Myelofibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myelofibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myelofibrosis Therapies and Key Companies
LNK01002: Lynk Pharmaceuticals
PU-H-71: Samus Therapeutics
TBX-2400: Taiga Biotechnologies
BMS-986158: Bristol-Myers Squibb
TP-3654: Sumitomo Pharma Oncology, Inc.
KER-050: Keros Therapeutics, Inc.
GB2064: Galecto Biotech AB
9-ING-41: Actuate Therapeutics Inc.
Selinexor: Karyopharm Therapeutics In
Navitoclax: AbbVie
Momelotinib: Sierra Oncology
Parsaclisib: Incyte Corporation

Myelofibrosis Market Drivers
Increase in R&D for the development of new and effective drug for the treatment • Increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Market Barriers
However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.
Scope of the Myelofibrosis Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others
Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others
Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies
Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Myelofibrosis Unmet Needs, KOL’s views, Analyst’s views, Myelofibrosis Market Access and Reimbursement

To know more about Myelofibrosis companies working in the treatment market, visit @ Myelofibrosis Clinical Trials and Therapeutic Assessment

Table of Contents
1. Myelofibrosis Market Report Introduction
2. Executive Summary for Myelofibrosis
3. SWOT analysis of Myelofibrosis
4. Myelofibrosis Patient Share (%) Overview at a Glance
5. Myelofibrosis Market Overview at a Glance
6. Myelofibrosis Disease Background and Overview
7. Myelofibrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Myelofibrosis
9. Myelofibrosis Current Treatment and Medical Practices
10. Myelofibrosis Unmet Needs
11. Myelofibrosis Emerging Therapies
12. Myelofibrosis Market Outlook
13. Country-Wise Myelofibrosis Market Analysis (2019–2032)
14. Myelofibrosis Market Access and Reimbursement of Therapies
15. Myelofibrosis Market Drivers
16. Myelofibrosis Market Barriers
17. Myelofibrosis Appendix
18. Myelofibrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.